Nontraditional management of basal cell carcinoma

Journal of Drugs in Dermatology

Volumn 12, Issue 5, 2013, Pages 526-532

  Botto, Nina ^a   Rogers, Gary ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; ETRETIN; FLUOROURACIL; GINSENG EXTRACT; IMIQUIMOD; ISOTRETINOIN; LEQ 506; PLACEBO; RESVERATROL; RETINOL; SARIDEGIB; SILYMARIN; SONIDEGIB; UNCLASSIFIED DRUG; VISMODEGIB;

ALTERNATIVE MEDICINE; ARTICLE; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CRYOSURGERY; DIET THERAPY; DYSGEUSIA; FOOD AND DRUG ADMINISTRATION; HAIR LOSS; HUMAN; MUSCLE SPASM; NONHUMAN; PHOTODYNAMIC THERAPY; PULSED DYE LASER; TEA; ANIMAL; CARCINOMA, BASAL CELL; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; SKIN NEOPLASMS; METHODOLOGY; REVIEW; SKIN TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; COMPLEMENTARY THERAPIES; HUMANS; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS;

EID: 84877634426     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283-287.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
3. Kricker A, Armstrong BK, English DR. Sun exposure and non-melanocytic skin cancer. Cancer Causes Control. 1994;5(4):367-392.
4. Seegenschmiedt MH, Oberste-Beulmann S, Lang E, Lang B, Guntrum F, Olschewski T. Radiotherapy for basal cell carcinoma. Local control and cosmetic outcome [in German]. Strahlenther Onkol. 2001;177(5):240-246.
5. Sei JF, Chaussade V, Zimmermann U, et al. Mohs' micrographic surgery: history, principles, critical analysis of its efficacy and indications [in French]. Ann Dermatol Venereol. 2004;131(2):173-182.
6. Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B. 2001;62(3):140-145.
7. Kuijpers DI, Thissen MR, Thissen CA, Neumann MH. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol. 2006;5(7):642-645.
8. Sayre RM, Dowdy JC, Gottschalk RW. Comparative effectiveness of clinically used light sources for cutaneous protoporphyrin IX-based photodynamic therapy. J Cosmet Laser Ther. 2011;13(2):63-68.
9. Braathen LR, Szeimies RM, Basset-Seguin N, et al; International Society for Photodynamic Therapy in Dermatology. Guidelines in the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56(1):125-143.
10. Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol. 2001;145(3):467-471.
11. Vinciullo C, Elliott T, Francis D, et al. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol. 2005;152(4):765-772.
12. Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol. 2003;149(6):1242-1249.
13. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 2001;144(4):832-840.
14. Foley P, Freeman M, Menter A, et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol. 2009;48(11):1236-1245.
15. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140(1):17-23.
16. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143(9):1131-1136.
17. Tope WD, Menter A, El-Azhary RA, et al. A comparison of topical methyl aminolevulinate photodynamic therapy versus placebo photodynamic therapy in nodular BCC. J Eur Acad Dermatol Venereol. 2004;18(suppl 2):413-414.
18. Steinbauer JM, Schreml S, Babilas P, et al. Topical photodynamic therapy with porphyrin precursors-assessment of treatment-associated pain in a retrospective study. Photochem Photobiol Sci. 2009;8(8):1111-1116.
19. Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel nonsurgical treatment for basal cell carcinomas: response and follow up 12-21 months after treatment. Lasers Surg Med. 2011;43(2):72-78.
20. Tran HT, Lee RA, Oganesyan G, Jiang SB. Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers Surg Med. 2012;44(6):459-467.
21. Efudex (fluorouracil) cream 5% [package insert]. Aliso Viejo, CA: Valeant Pharmaceuticals International; 2005.
22. Aldara (imiquimod) cream 5% [package insert]. St Paul, MN: 3M Pharmaceuticals; 2004.
23. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells mimic cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002;218(1-2):74-86.
24. Dillaha CJ, Jansen GT, Honeycutt WM, Bradford AC. Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol. 1983;119(9):774-783.
25. Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33(4):433-439.
26. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose response trial. J Am Acad Dermatol. 2001;44(5):807-813.
27. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722-733.
28. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47(3):390-398.
29. Vidal D, Matias-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol. 2007;143(2):266-268.
30. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18(6):677-682.
31. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138(9):1165-1171.
32. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145(12):1431-1438.
33. Leppala J, Kaarniranta K, Uusitalo H, Kontkanen M. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand. 2007;85(5):566-568.
34. Prokosch V, Thanos S, Spaniol K, Stupp T. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids. Graefes Arch Clin Exp Opthalmol. 2011;249(1):121-125.
35. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition. 2000;16(11-12):1084-1089.
36. Clouser MC, Roe DJ, Foote JA, Harris RB, Alberts DS. Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. Nutr Cancer. 2010;62(8):1058-1066.
37. Steele VE, Hawk ET, Viner JL, Lubet RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res. 2003;523-524:137-144.
38. Clouser MC, Roe DJ, Foote JA, Harris RB. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. Pharmacoepidemiol Drug Saf. 2009;18(8):276-283.
39. Grau MV, Baron JA, Langholz B, et al. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer. 2006;119(3):682-686.
40. Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia. 2009;11(1):96-101.
41. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502-2511.
42. Sekulic A. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Presented at: 7th European Association of Dermato-Oncology Congress; Nantes, France; June 20-23, 2011.
43. Amin SH, Tibes R, Kim JE, Hybarger CP. Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. Laryngoscope. 2010;120(12):2456-2459.
44. http://www.pathway2curis.com/novartis-pharmaceuticals-lde225-leq506- hedgehog-inihbitor-t9. tml Accessed March 31, 2013.
45. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131(8):1735-1744.
46. Tang JY, So PL, Epstein EH Jr. Novel Hedgehog pathway targets against basal cell carcinoma. Toxicol Appl Pharmacol. 2007;224(3):257-264.
47. Tremblay MR, Lescarbeau A, Grogan MJ, et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem. 2009;52(14):4400-4418.
48. Tabs S, Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol. 2004;14(2):96-102.
49. Huang MT, Ho CT, Wang ZY, et al. Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res. 1994;54(3):701-708.
50. Mitamura T, Matsuno T, Sakamoto S, et al. Effects of a new clerodane diterpenoid isolated from propolis on chemically induced skin tumors in mice. Anticancer Res. 1996;16(5A):2669-2672.
51. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res. 1999;59(3):622-632.
52. Xiaoguang C, Hongyan L, Xiaohong L, et al. Cancer chemopreventive and therapeutic activities of red ginseng. J Ethnopharmacol. 1998;60(1):71-78.
53. Ghoneum M, Jewett A. Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro. Cancer Detect Prev. 2000;24(4):314-324.
54. Chobotova K, Vernallis AB, Majid FA. Bromelain's activity and potential as an anti-cancer agent: Current evidence and perspectives. Cancer Lett. 2010;290(2):148-156.
55. Kalra N, Bhui K, Roy P, et al. Regulation of p53, nuclear factor kappaB and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skin. Toxicol Appl Pharmacol. 2008;226(1):30-37.
56. Katiyar SK. Green tea prevents non-melanoma skin cancer by enhancing DNA repair. Arch Biochem Biophys. 2011;508(2):152-158.
57. Nomura M, Ma WY, Huang C, et al. Inhibition of ultraviolet B-induced AP-1 activation by theaflavins from black tea. Mol Carcinog. 2000;28(3):148-155.
58. Zhao J, Jin X, Yaping E, et al. Photoprotective effect of black tea extracts against UVB-induced phototoxicity in skin. Photochem Photobiol. 1999;70(4):637-644.
59. Javed S, Mehrotra NK, Shukla Y. Chemopreventive effects of black tea polyphenols in mouse skin model of carcinogenesis. Biomed Environ Sci. 1998;11(4):307-313.
60. Lu YP, Lou YR, Xie JG, Yen P, Huang MT, Conney AH. Inhibitory effect of black tea on the growth of established skin tumors in mice: effects on tumor size, apoptosis, mitosis, and bromodeoxyuridine incorporation into DNA. Carcinogenesis. 1997;18(11):2163-2169.
61. Huang MT, Xie JG, Wang ZY, et al. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically important constituent of tea. Cancer Res. 1997;57(13):2623-2629.
62. Aziz MH, Reagan-Shaw S, Wu J, Longley BJ, Ahmad N. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J. 2005;19(9):1193-1195.
63. Mudigonda T, Pearce DJ, Yentzer BA, Williford P, Feldman SR. The economic impact of non-melanoma skin cancer: a review. J Natl Compr Canc Netw. 2010;8(8):888-896.
64. Ravitskiy L, Brodland DG, Zitelli JA. Cost analysis: Mohs micrographic surgery. Dermatol Surg. 2012;38(4):585-594.
65. Chen JG, Fleischer AB Jr, Smith ED, et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg. 2001;27(12)1035-1038.
66. Rogers HW, Coldiron BM. A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption. J Am Acad Dermatol. 2009;61(1):96-103.
67. Aguilar M, de Troya M, Martin L, Benitez N, Gonzalez M. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities. J Eur Acad Dermatol Venereol. 2010; 24(12):1431-1436.
68. Avril M, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer. 1997;76(1):100-106.
69. Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol. 1989;15(4):424-431.
70. Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol. 1986;37(1):33-34.
71. Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol. 2008;9(12):1149-1156.
72. Thissen MR, Nieman FH, Ideler AH, Berretty PJ, Neumann HA. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg. 2000;26(8):759-764.
73. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumors using delta-aminolevulinic acid and desferrioxamine. Br J Dermatol. 1995;133(2):282-288.
74. Fink-Puches R, Soyer HP, Hofer A, Kerl H, Wolf P. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol. 1998;134(7):821-826.
75. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990;6(1-2):143-148.
76. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of nonmelanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol. 1994;130(6):743-751.
77. Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with deltaaminolaevulinic acid for nodular basal cell carcinomas using prior debulking technique. Br J Dermatol. 2000;142(2):338-339.
78. Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg. 2005;31(3):318-323.
79. Quirk C, Gebauer K, Owens M, et al. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol. 2006;47(4):258-265.
80. Vun Y, Siller G. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol. 2006;47(3):169-171.
81. Tangrea JA, Edwards PK, Taylor PR, et al. Long-term therapy with lowdose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Carcinoma Study Group. J Natl Cancer Inst. 1992;84(5):328-332.
82. Moon TE, Levin N, Cartmel B, et al. effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6(11):949-956.
83. Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell skin cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med. 1990;323(12):789-795.